Twist Bioscience CORP Form 4 insider transactions

Director Robert Chess of Twist Bioscience Corp. executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

A Twist Bioscience executive, Dennis Cho, sold 1,507 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience's President and COO, Patrick John Finn, sold 10,340 shares of common stock to cover tax obligations related to vesting restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,347 shares of common stock to cover tax obligations related to vesting restricted stock units.

Twist Bioscience CEO Emily Leproust sold 7,968 shares of common stock to cover tax obligations related to vesting restricted stock units.

Emily Leproust, CEO of Twist Bioscience, sold 14,334 shares of common stock on November 6, 2024, to cover tax obligations related to vesting performance stock units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold 1,448 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 5,519 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Adam Laponis, CFO of Twist Bioscience, sold 4,160 shares of common stock on November 6, 2024, to satisfy tax withholding obligations related to vesting Performance Stock Units.

Patrick John Finn, COO of Twist Bioscience, sold 6,239 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Dennis Cho, a Twist Bioscience executive, sold 1,811 shares of common stock on November 6, 2024, to cover tax obligations related to vesting Performance Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, reports the acquisition and disposition of company stock to cover tax obligations related to vesting restricted stock units.

Dennis Cho, a Senior Vice President at Twist Bioscience, reports the acquisition and disposal of company stock related to the vesting of performance stock units (PSUs) and subsequent tax obligations.

CEO Emily Leproust reports acquisition of shares through performance stock units and subsequent sale to cover tax obligations.

Patrick John Finn, COO of Twist Bioscience, reports the acquisition of shares through performance stock unit (PSU) vesting and subsequent sale of shares to cover tax obligations.

Adam Laponis, CFO of Twist Bioscience, reports the acquisition of 20,000 shares of common stock on November 4, 2024, as a result of performance stock units meeting their target criteria.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, reports acquisition of 8,500 shares and sale of 156 shares to cover tax obligations.

Patrick John Finn, COO of Twist Bioscience, sold 2,261 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Adam Laponis, CFO of Twist Bioscience, sold 856 shares of common stock on October 9, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 3,310 shares of common stock on October 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

CEO Emily Leproust sold shares of Twist Bioscience to cover tax withholding obligations related to vesting Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 6,865 shares of common stock on October 2, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 234 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 297 shares of common stock on September 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

CEO of Twist Bioscience, Emily Leproust, sold 1,730 shares of common stock on September 20, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience Corp, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 275 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, reports selling 912 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience, sold 240 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.